Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma

M. Auvray; E. Auclin; P. Barthelemy; P. Bono; P. Kellokumpu-Lehtinen; M. Gross-Goupil; G. De Velasco; T. Powles; G. Mouillet; Y.-A. Vano; G. Gravis; L. Mourey; F. Priou; F. Rolland; B. Escudier; L. Albiges

doi:10.1016/j.ejca.2018.11.031

Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma

M. Auvray
, E. Auclin
, P. Barthelemy
, P. Bono
, P. Kellokumpu-Lehtinen
, M. Gross-Goupil
, G. De Velasco
, T. Powles
, G. Mouillet
, Y.-A. Vano
, G. Gravis
, L. Mourey
, F. Priou
, F. Rolland
, B. Escudier
, L. Albiges

Research output: Contribution to journal › Article › Scientific › peer-review

117 Citations (Scopus)

Original language	English
Pages (from-to)	33-40
Journal	EUROPEAN JOURNAL OF CANCER
Volume	108
DOIs	https://doi.org/10.1016/j.ejca.2018.11.031
Publication status	Published - 2019
Publication type	A1 Journal article-refereed

Keywords

Immunotherapy
Ipilimumab
Metastatic renal cell carcinomas
Nivolumab
Outcomes
Second-line tyrosine kinase inhibitors

Publication forum classification

Publication forum level 2

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejca.2018.11.031

Cite this

Auvray, M., Auclin, E., Barthelemy, P., Bono, P., Kellokumpu-Lehtinen, P., Gross-Goupil, M., De Velasco, G., Powles, T., Mouillet, G., Vano, Y.-A., Gravis, G., Mourey, L., Priou, F., Rolland, F., Escudier, B., & Albiges, L. (2019). Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. EUROPEAN JOURNAL OF CANCER, 108, 33-40. https://doi.org/10.1016/j.ejca.2018.11.031

@article{f46929ef08ee44b8a400062d209f110f,

title = "Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma",

keywords = "Immunotherapy, Ipilimumab, Metastatic renal cell carcinomas, Nivolumab, Outcomes, Second-line tyrosine kinase inhibitors, Immunotherapy, Ipilimumab, Metastatic renal cell carcinomas, Nivolumab, Outcomes, Second-line tyrosine kinase inhibitors",

author = "M. Auvray and E. Auclin and P. Barthelemy and P. Bono and P. Kellokumpu-Lehtinen and M. Gross-Goupil and \{De Velasco\}, G. and T. Powles and G. Mouillet and Y.-A. Vano and G. Gravis and L. Mourey and F. Priou and F. Rolland and B. Escudier and L. Albiges",

year = "2019",

doi = "10.1016/j.ejca.2018.11.031",

language = "English",

volume = "108",

pages = "33--40",

journal = "EUROPEAN JOURNAL OF CANCER",

issn = "0959-8049",

publisher = "Elsevier",

}

Auvray, M, Auclin, E, Barthelemy, P, Bono, P, Kellokumpu-Lehtinen, P, Gross-Goupil, M, De Velasco, G, Powles, T, Mouillet, G, Vano, Y-A, Gravis, G, Mourey, L, Priou, F, Rolland, F, Escudier, B & Albiges, L 2019, 'Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma', EUROPEAN JOURNAL OF CANCER, vol. 108, pp. 33-40. https://doi.org/10.1016/j.ejca.2018.11.031

TY - JOUR

T1 - Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma

AU - Auvray, M.

AU - Auclin, E.

AU - Barthelemy, P.

AU - Bono, P.

AU - Kellokumpu-Lehtinen, P.

AU - Gross-Goupil, M.

AU - De Velasco, G.

AU - Powles, T.

AU - Mouillet, G.

AU - Vano, Y.-A.

AU - Gravis, G.

AU - Mourey, L.

AU - Priou, F.

AU - Rolland, F.

AU - Escudier, B.

AU - Albiges, L.

PY - 2019

Y1 - 2019

KW - Immunotherapy

KW - Ipilimumab

KW - Metastatic renal cell carcinomas

KW - Nivolumab

KW - Outcomes

KW - Second-line tyrosine kinase inhibitors

KW - Immunotherapy

KW - Ipilimumab

KW - Metastatic renal cell carcinomas

KW - Nivolumab

KW - Outcomes

KW - Second-line tyrosine kinase inhibitors

U2 - 10.1016/j.ejca.2018.11.031

DO - 10.1016/j.ejca.2018.11.031

M3 - Article

SN - 0959-8049

VL - 108

SP - 33

EP - 40

JO - EUROPEAN JOURNAL OF CANCER

JF - EUROPEAN JOURNAL OF CANCER

ER -